Only a handful of places left for our September 2026 cohort. Applications close soonApply now →

MSTA
Your future
starts here.

Exosomes

Also known as: exosome, extracellular vesicles, EVs, biosomes

Extracellular vesicles are lipid-bilayer particles released by cells that cannot replicate. “Exosome” names those of demonstrated endosomal origin, not a size class. In professional skincare, EV-containing preparations are applied topically after procedures that open the skin.

Evidence status

Emerging

Vesicle biology is well established. The aesthetic clinical evidence cited here is a single uncontrolled, sponsor-run report of one named product, with no comparator arm and participant yes/no outcomes. It cannot isolate an EV effect, and it does not transfer to any other preparation.

What exosomes are, and the preparations available#

An extracellular vesicle is a particle released from a cell, bounded by a lipid bilayer, that cannot replicate on its own.[2] Vesicles are not cells and they are not alive. They carry proteins, lipids, messenger RNA and microRNA from the cell that produced them to the cells that receive them.

Nomenclature and endosomal origin

“Exosome” is a biogenesis term. It names vesicles that come from the endosomal pathway, which is a statement about where a vesicle was made rather than about how large it is.[2]

Where a supplier can demonstrate that origin, “exosome” is the accurate word. Where it cannot, small EV and EV-containing preparation are, and the difference between the two descriptions is the difference between what is in the bottle and what is on the label.

Categories of vesicle preparation

Native extracellular vesicles, artificial cell-derived vesicles produced by deliberately disrupting cells, and synthetic vesicles built de novo from molecular components are distinct things.[2] Evidence for one is not evidence for another, which makes the category a product belongs to part of what a supplier is being asked to state.

Use of exosome preparations in aesthetic practice#

Route and origin, rather than efficacy, decide what may lawfully be used, and both are settled the same way in Great Britain and Northern Ireland.

Route and cosmetic status

In both jurisdictions, products intended to be ingested, inhaled, injected or implanted are not classified as cosmetic products at all.[4, 5] Route decides the category before anything else does: a preparation lawfully on the market as a topical cosmetic is yours to apply and to retail, while an injected preparation is not a cosmetic product.

That settles the category and not the classification. Whether a given injectable EV preparation is a medicinal product is assessed for that product, from its claims, its presentation to the public, the pharmacological, metabolic or immunological properties of its ingredients, and its intended purpose.[7] “Not a cosmetic” and “therefore a medicine” are two different findings.

Human-origin material in cosmetics

Annex II of the Cosmetics Regulation is the list of substances prohibited in cosmetic products. Reference number 416 is “cells, tissues or products of human origin”. Great Britain applies the assimilated Regulation; Northern Ireland applies EU Regulation 1223/2009 itself, a separate regime with its own Responsible Person and notification requirements.[4, 5, 6] The prohibition is in both.

Requirements attaching to a topical cosmetic

Topical use is a route rather than an authorisation. A topical cosmetic still has to meet the composition, Responsible Person, safety assessment, product information file, notification, labelling and claims requirements of the regime where it is placed on the market.[4, 5] “Applied topically” answers the route question and nothing else.

This is a developing area, and the position is worth confirming at the point any claim is made in marketing or consultation. The product’s source and intended use belong in the treatment record.

Contraindications and cautions#

None of the sources reviewed here establishes a client-level contraindication specific to EV-containing preparations. What governs the screening is the procedure the preparation accompanies: topical application after microneedling or laser inherits that procedure’s contraindications in full, and a client who is not a candidate for the procedure is not a candidate for the combined treatment.

A deliberately breached barrier

Applying a biologically active preparation into channels that have just been made for it raises sterility and provenance to the same level of importance. A single-use, sealed presentation and an aseptic technique are the conditions under which that is done, and a preparation whose composition and lawful use cannot be accounted for does not meet them.

Clinical uses and the evidence behind them#

Every nucleated cell releases extracellular vesicles, and their role in intercellular signalling is well established across oncology, immunology and regenerative medicine as well as aesthetics.[2]That much is not in dispute. The aesthetic question — what a bottle of them does to a face — rests on a single cited human report.

Application after standard microneedling

One uncontrolled, sponsor-run report followed more than 100 people given three sessions of standard microneedling plusa named human umbilical-cord Wharton’s-jelly MSC-derived product, at four- to six-week intervals. There was no microneedling-only arm and no vehicle arm. Outcomes were participant yes/no questionnaire responses, and the photographs and questionnaires were shared with the sponsor for analysis.[3]

What it shows is that participants reported improvement after the combined protocol. What it cannot show is how much of that came from the product rather than from the microneedling, because no arm exists that would separate the two. Collagen and fibroblasts were not measured at all: increased fibroblast proliferation and collagen synthesis appear in the paper as the authors’ proposed mechanism, not as a result.[3]

Provenance of the cited report

The provenance belongs in the same sentence as the finding. The lead author is Chief Medical Officer of the product’s manufacturer, four of the six authors held positions in the company group, and the paper discloses consultative or financial relationships between several investigators and that group. None of that makes the observation false. It does mean it is a company report of its own product, and it is read as one.

Scope of the cited evidence

The report evaluated one named product applied after standard microneedling. It establishes no timing comparison, no use after radiofrequency microneedling or laser, no use beneath an occlusive, no reduced downtime, no optimal interval and no expectation of when a result should appear.[3] Nor does it carry across to another preparation or another device: source species and tissue, vesicle content, isolation method and stability vary enormously between suppliers, and native EVs, cell-derived mimetics and synthetic particles are not the same category of thing.[2]

Selecting a preparation and establishing its provenance#

With no comparative evidence between products, selection does not turn on which preparation performs best. It turns on which preparation can be accounted for — what the material was harvested from, and what the manufacturer’s own instructions say about using it.

Source species and tissue

The question that resolves provenance is what species and tissue the source cells came from, answered in writing. Plant-derived, bacterial, other mammalian-cell-derived, engineered cell-derived and fully synthetic preparations are different categories with different evidence and different legal positions.[2]A supplier who answers “bio-identical” has not answered.

Laboratory culture and human origin

Suppliers routinely offer “lab-made” or “bio-identical” as the compliant alternative to human-derived material. Neither is a recognised scientific or regulatory category, and the framing conceals the issue Annex II turns on: vesicles harvested from cultured human cells are still products of human origin. The product in the one human report reviewed here was itself grown in laboratory culture — from human umbilical-cord Wharton’s-jelly cells.[2, 3] Where a preparation was made describes the site of production; what it was made from is a separate question, and it is the one the prohibition addresses.

Preparations in UK circulation

The question is not theoretical. A November 2025 undercover investigation contacted 50 UK clinics offering exosome treatments; 40 disclosed the brand they used, most of them plant- or salmon-derived, and almost a quarter admitted to products derived from human stem cells, naming umbilical cords and fat cells.[8]

Product-specific instructions

There is no generic exosome protocol to fall back on. The operative guidance is the lawful intended use of the exact product, the storage, reconstitution and handling instructions issued for it, and the instructions for the exact procedure it accompanies.[3]

The consultation

Clients increasingly arrive already knowing the word “exosomes”, which changes the task from introducing a concept to setting an expectation. What can be said accurately is that the vesicle biology is real, that the aesthetic evidence is one uncontrolled company report of one product, and that no published work has yet measured how much the product adds to the procedure it accompanies.

Adverse effects and their management#

Effects attributable to the preparation

None of the sources reviewed here characterises the adverse effects of EV-containing preparations in aesthetic use. The one clinical report reviewed here recorded participant yes/no questionnaire responses and had no comparator arm,[3] so nothing in it separates a reaction to the preparation from a reaction to the microneedling it accompanied.

A preparation whose composition and lawful status cannot be established is also one whose adverse-effect profile cannot be anticipated, which is why provenance and the manufacturer’s own handling instructions carry the weight that trial data would otherwise carry.

Reducing, stopping and referring

No source reviewed here establishes a reaction pattern, a threshold for stopping or a referral trigger specific to an EV-containing preparation, so there is no product-level rule to set against the procedure’s own. The screening, aftercare and reaction-management standards of the accompanying procedure remain the operative ones, alongside the handling and use instructions issued for the exact product.[3]

Referral and scope boundaries#

The boundaries in this category are drawn by route, by origin and by what may be claimed rather than by clinical judgement, which means they are settled before a client is assessed rather than in response to one. Three apply:

  • Injected preparations. Injection is not a cosmetic route in either jurisdiction,[4, 5] and whether a specific injectable is a medicinal product is a product-by-product assessment rather than a judgement made in a treatment room.[7]
  • Preparations of human origin. Annex II reference 416 prohibits cells, tissues or products of human origin in cosmetic products,[4, 5, 6] so a preparation disclosed as human-derived sits outside what may lawfully be applied as a cosmetic.
  • Claims made about the treatment.Describing topical EV application as a medical treatment, or implying an authorisation the product does not hold, sits outside what the product’s status supports.

Inside those boundaries the aesthetic work is unaffected. The procedure itself, its aftercare, and the accuracy of what is said about the preparation all remain within remit, and they account for everything the sources reviewed here can support.

Mechanism of action#

The proposed aesthetic mechanism runs through wound healing. The cascade progresses through haemostasis, inflammation, proliferation and remodelling; fibroblast activity during the proliferative phase is what ultimately produces new collagen, and fibroblasts are regulated by signalling molecules in their local environment. EV preparations are proposed to influence that environment.

Proposed is the operative word. The cascade is well described and the signalling role of vesicles within it is plausible; the step from that biology to a measured aesthetic outcome is the argument for the product rather than anything produced by it.

Commonly misstated claims#

Four statements circulate widely in the trade. Each is set out below with what the primary literature was found to support.

“A vesicle of about 100 nanometres is an exosome.”

Size is the usual shorthand and it is not the definition. “Exosome” is a biogenesis term naming vesicles from the endosomal pathway; the international consensus discourages biogenesis terms unless subcellular origin can be demonstrated for the specific source and condition, and states that small EV and exosome are not synonyms.[2]The size range most often quoted — roughly 40 to 160 nanometres, averaging about 100 — comes from a definition that carries endosomal origin in the same sentence.[1]

Supported statement: a preparation of small extracellular vesicles, called an exosome preparation only where endosomal origin has been demonstrated.

“Exosome treatments deliver stem cells.”

“Stem cell derived” describes where the vesicles were harvested from rather than what is in the bottle. An extracellular vesicle is a particle released from a cell, bounded by a lipid bilayer, that cannot replicate on its own.[2] Reputable suppliers do not make the claim; it survives mostly in consumer-facing description of the treatment.

Supported statement: vesicles harvested from a cell culture, with no living cells present in the preparation.

“The MHRA classifies injected exosomes as medicinal products.”

The sentence appears on clinic sites, in trade guidance and in insurer briefings. No published MHRA determination, safety communication or authorisation deals specifically with exosome preparations in aesthetics.[no source found] It may well be the agency’s position; it is not a record that can be shown. What can be shown is that injection is not a cosmetic route in either jurisdiction[4, 5] and that medicinal status is assessed for the individual product.[7]

Supported statement: an injected preparation is not a cosmetic product, and whether it is a medicinal product is assessed product by product.

“Exosomes stimulate fibroblasts and increase collagen.”

The claim states as a finding what the cited report offered as a hypothesis.[3]

Supported statement: participants reported improvement after three sessions of microneedling with one named product, and no collagen or fibroblast outcome was measured.

Areas of remaining uncertainty#

  • The size of any effect the preparation adds to the procedure. The one cited report had no comparator arm, which leaves selection resting on a product’s documentation rather than on a measured benefit.
  • Whether collagen or fibroblast activity changes at all in aesthetic use. Nothing has measured it, which puts a collagen outcome outside what may be stated in consultation or marketing.
  • How far one product’s evidence describes another. Source species and tissue, vesicle content, isolation method and stability differ between suppliers, so each preparation is a separate decision rather than an instance of a category.
  • Whether meaningful quantities reach the viable epidermis and dermis through microneedling channels. The premise is reasonable and cannot be verified in routine practice, which keeps the delivery rationale an argument rather than a finding.
  • The regulatory picture, part of which is not publicly documented at all. That makes verification at the point a claim is made, rather than reliance on a trade summary, the defensible position.

Frequently asked questions#

Are exosome preparations lawful in UK clinics?

Topical EV-containing products are in use in UK clinics. Injection is not a cosmetic route in either Great Britain or Northern Ireland,[4, 5] and Annex II entry 416 prohibits cells, tissues or products of human origin in cosmetic products.[4, 5, 6] Whether a specific injectable preparation is a medicinal product is a product-by-product assessment.[7]

Is a “lab-made” or “bio-identical” preparation compliant?

Those are marketing words rather than regulatory categories, and they do not answer the question. Vesicles cultured from human cells remain of human origin.[2, 3] The question that does answer it is what species and tissue the source cells came from.

Can an EV preparation be used without microneedling?

The only human report cited here applied the product after standard microneedling, so it says nothing either way about use on intact skin.[3] The delivery rationale for applying them after a procedure is a reasonable argument that has not been tested against the alternative.

How soon does a result appear?

No cited source establishes a timeframe. The one report assessed participants four to six weeks after their third session and asked them yes/no questions; it compared no time points and measured no course of a response.[3] Claims about faster settling or shorter downtime have no source behind them.[3]

How do EV preparations differ from polynucleotides?

Both sit under the regenerative heading and differ in material and in route. Polynucleotides are purified DNA fragments, usually injected. EV preparations are vesicles, applied topically in UK practice.

References#

Each source is graded by evidence tier. Tier 4 material (manufacturer documents, expert consensus, practitioner experience) is useful for protocol and context, and is never presented as equivalent to independent clinical evidence.

  1. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977.Tier 4Supports: General extracellular-vesicle biology and the role of vesicles in intercellular signalling. Describes exosomes as EVs 'with a size range of ~40 to 160 nm (average ~100 nm) in diameter with an endosomal origin'. NOTE: the article reports no systematic search or selection method, so it is a narrative review, not a systematic one. Use for background biology only.Funding / interest: Supported by research funds from MD Anderson Cancer Center and by NCI grants RO1 CA213233, RO1 CA195733 and CA 231465. Declared: 'MD Anderson Cancer Center and R.K. hold patents in the area of exosome biology and are licensed to Codiak Biosciences, Inc. MD Anderson Cancer Center and R.K. are stock equity holders in Codiak Biosciences, Inc. R.K. is a consultant and scientific adviser for Codiak Biosciences, Inc. V.S.L. is a paid consultant for Codiak Biosciences, Inc.'
  2. Welsh JA, Goberdhan DCI, O'Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. Journal of Extracellular Vesicles. 2024;13(2):e12404.Tier 4Supports: The consensus position of the International Society for Extracellular Vesicles on nomenclature. Defines an extracellular vesicle as a particle released from a cell, delimited by a lipid bilayer, that cannot replicate on its own. States that 'biogenesis terms are discouraged unless subcellular origin can be demonstrated for the specific EV source and condition', and that 'sEV (for small EV) and exosome are not synonymous'. Separately defines artificial cell-derived vesicles (EV mimetics produced under induced cell disruption, such as extrusion) and synthetic vesicles (EV mimetics synthesised de novo from molecular components, or hybrids).
  3. Cicchetti C, Mazzeo M, Heke M, Crowley M, Crowley E, Ntonos A. Topical Wharton's Jelly MSC-derived Age Zero exosome treatments after micro-needling for skin rejuvenation. Journal of Cosmetic Dermatology. 2024.Tier 3Supports: An uncontrolled report of more than 100 participants given three sessions of microneedling (SkinPen Precision) plus a named human umbilical-cord Wharton's-jelly MSC-derived product at four- to six-week intervals, assessed four to six weeks after the last session. THERE WAS NO MICRONEEDLING-ONLY AND NO VEHICLE ARM. Outcomes were participant yes/no questionnaire responses; photographs and questionnaires were shared with the sponsor for analysis. Collagen and fibroblasts were not measured — increased fibroblast proliferation and collagen synthesis appear only as the authors' proposed mechanism. Supports only that participants reported improvement after the combined protocol, for that exact product and protocol.Funding / interest: Sponsor-run and product-owner-authored. States 'the authors received no specific funding for this work', which does not describe the study's provenance: the lead author is Chief Medical Officer of Regenerelle, the product's manufacturer, and the paper discloses consultative or financial relationships between several investigators and the affiliated company group. Four of the six authors held positions at the company group; one investigator was external.
  4. Office for Product Safety and Standards. Regulation 20091223 and the Cosmetic Products Enforcement Regulations 2013: Great Britain. GOV.UK.Tier 1Supports: The law applying in Great Britain is Regulation (EC) No 1223/2009 as amended by the Product Safety and Metrology etc. (Amendment etc.) (EU Exit) Regulations 2019. A cosmetic product's field of application is 'the epidermis, the hair system, the nails, the lips, the external genital organs, the teeth, the mucous membranes of the oral cavity'. States: 'Products that are intended to be ingested, inhaled, injected or implanted are not classified as cosmetic products.' Annex II lists ingredients prohibited in all cosmetics.
  5. Office for Product Safety and Standards. Regulation 20091223 and the Cosmetic Products Enforcement Regulations 2013: Northern Ireland. GOV.UK.Tier 1Supports: Northern Ireland applies EU Regulation (EC) No 1223/2009 itself, not the Great Britain version — a separate regime with its own Responsible Person and notification requirements (CPNP rather than the GB service). The same exclusion applies: 'Products that are intended to be ingested, inhaled, injected or implanted are not classified as cosmetic products.'
  6. Regulation (EC) No 1223/2009 on cosmetic products, Annex II — list of substances prohibited in cosmetic products, reference number 416. legislation.gov.uk (assimilated law as it applies in Great Britain).Tier 1Supports: Annex II reference number 416 is 'Cells, tissues or products of human origin'. Annex II is the list of substances prohibited in cosmetic products.
  7. Medicines and Healthcare products Regulatory Agency. Borderline products: how to tell if your product is a medicine. GOV.UK. Last updated 2 July 2026.Tier 1Supports: How the MHRA assesses whether a product is a medicinal product: 'the claims about what the product does (explicit and implicit)'; 'how it is presented to the public through labelling, packaging, promotional literature, advertisements, websites, social media and customer reviews'; 'the pharmacological, metabolic or immunological properties of the ingredients'; 'the primary intended purpose of the product or the manner in which it would be used by consumers'; and whether similar licensed products exist. The assessment is of the individual product.
  8. Aesthetics journal. Investigation reports human-derived exosomes in UK clinics. 17 November 2025, reporting a 5 News undercover investigation.Tier 4Supports: 5 News contacted 50 clinics across Bristol, Cardiff, Glasgow, London and Liverpool. Forty of the 50 disclosed the exosome brand used; most were plant- or salmon-derived. Almost a quarter admitted to products derived from human stem cells, naming umbilical cords and fat cells as the tissue sources. A Department for Business and Trade spokesperson is quoted: 'Cosmetics containing exosomes from humans are banned in the UK. Although we have not seen an increase in reports of non-compliance, we urge anyone with concerns to contact their local Trading Standards department or Citizens Advice.' A trade report of a broadcast investigation, not a regulatory record or a prevalence study.

Continue learning with MSTA#

Skinipedia is written by the educators at MSTA, the medic-led skincare training academy in Liverpool.